FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
13 sept. 2023 13h34 HE
|
FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 16h05 HE
|
Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
08 août 2023 16h05 HE
|
Icosavax, Inc.
- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
20 juin 2023 08h00 HE
|
Icosavax, Inc.
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
10 mai 2023 16h05 HE
|
Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
26 avr. 2023 12h15 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
30 mars 2023 16h05 HE
|
Icosavax, Inc.
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of...
New Technology Can Now Test for Airborne COVID and Several Strains of the Common Flu
01 mars 2023 23h35 HE
|
AirAnswers Inc
NORTH CHICAGO, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- AirAnswers, the leader in air sampling and testing technology, is expanding their test offering to include a panel of airborne viruses...
Icosavax to Participate in the Upcoming Healthcare Conferences
28 févr. 2023 08h00 HE
|
Icosavax, Inc.
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Granted FDA Fast Track Designation for IVX-A12
21 févr. 2023 08h00 HE
|
Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...